ARTICLE SUMMARY:
Inspired to improve upon an off-label treatment, a Minneapolis-based start-up offers chronic migraine patients a dedicated solution.
ShiraTronics CEO Rob Binney got his start on the commercial side of the pharmaceutical industry in the 1990s before shifting to medtech and working at Boston Scientific during an explosive growth period. Later, Binney would be introduced to the founders of AccessClosure, who convinced him to join the company, marking his transition to the world of device start-ups in the Bay Area and later Minneapolis. Binney served his first CEO role at Alydia Health, which focused on postpartum bleeding. “At that time,” he recalls, “I committed, for the remainder of my career, to being a part of innovative platforms that allow us to transform the way patients are treated.”
To that end, Binney became part of ShiraTronics, a company focused on bringing an intentional and dedicated solution to drug-resistant chronic migraine patients. Chronic migraine is a highly debilitating condition characterized by 15 or more headache days per month, at least eight of which exhibit distinct migraine features. The first line of treatment for chronic migraine is typically triptans, a class of selective serotonin receptor agonists that constrict dilated blood vessels and inhibit pain signals, followed by calcitonin gene-related peptide (CGRP) inhibitors or Botox injections.
